Additional data from Minoryx’s Phase 2/3 ADVANCE clinical trial presented at American Neurological Association (ANA) 2021

by Minoryx Therapeutics

​Presentation highlights reduction in cerebral lesion progression and the risk of developing cerebral ALD in AMN patients based on MRI and plasma biomarker data.

Read more

Minoryx publishes mechanism of action of leriglitazone in X-ALD in Science Translational Medicine journal

by Minoryx Therapeutics

Published data highlights therapeutic potential for all forms of X-ALD as well as other neurodegenerative and neuroinflammatory diseases

Read more

Covid-19 drives innovation and makes healthcare investment spike

by Biocat

Covid-19 pandemic has boosted cutting-edge research and innovation, reaching a record investment for companies in the BioRegion

Read more

Minoryx recibe la aprobación de la Agencia Reguladora Española para iniciar el estudio de fase 2 en la ataxia de Friedreich

by Minoryx Therapeutics

La ataxia de Friedreich es una enfermedad rara neurodegenerativa que se diagnostica antes de los 25 años. En España afecta a unas 2.000 personas. El ensayo FRAMES iniciará el reclutamiento de pacie...

Read more

Minoryx raises 1.6M€ in a round led by Caixa Capital Risc

by Expansión

La Caixa is leading this operation through the Caixa Innvierte BioMed II fund, joined by the Sanfilippo Foundation Switzerland

Read more
Subscribe to Directory
Write an Article

Recent News

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

El diagnóstico genético neonatal mejor...

Un estudio con datos de los últimos 35 años, ind...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Bio & Tech Smart Capital invierte en AD...

by Noso Capital

Bio & Tech Smart Capital FCRE, fondo de capital riesgo de Noso Capital...

Photos Stream